Document text
Principal Investigator: Mariette Barbier
Organization: WEST VIRGINIA UNIVERSITY
Fiscal Year: 2022
Award: $204,972
Funding agency: National Institute of Allergy and Infectious Diseases
Project Summary
Lyme disease is an endemic tick-borne disease associated with debilitating manifestations such as arthritis,
muscle pain, carditis, meningitis, and encephalomyelitis. Despite extensive efforts in the field, there is still no
vaccine for the prevention of this infection available for human use. To address this problem, our laboratory has
developed novel methodologies to identify antigens relevant during bacterial infection in ticks and mammals and
design peptide antigens based on extracellular and conserved regions of these proteins. Through the work
proposed in the parent application, we are selecting and evaluating outer-membrane proteins expressed in
various phases of the enzootic cycle of B. burgdorferi as vaccine antigens against Lyme disease. This is currently
performed using peptide and recombinant protein-based vaccines. In this supplement, we propose to expand
vaccine formulations to the mRNA vaccine platform. We have secured partners that will generate mRNA
constructs encoding the antigens of interest and encase them in world class clinical grade lipid nanoparticles.
We will first validate the mRNA technology for in vitro and in vivo expression and immunogenicity, and perform
head-to-head comparisons with the peptide and recombinant formulations. We will use veterinary Lyme vaccines
for comparison. At the conclusion of this work, we will have evaluated a novel platform for Lyme vaccine
development and generated essential pre-clinical data to enable transition to clinical studies for the development
of a vaccine against Lyme disease in humans.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Aching muscles><Address><Adjuvant><Affect><Antigenic Determinants><Antigens><Area><Arthritis><B burgdorferi><B pertussis><B. burgdorferi><B. pertussis><Bacteria><Bacterial Antigens><Bacterial Infections><Binding Determinants><Biotech><Biotechnology><Bordetella pertussis><Borrelia><Borrelia burgdorferi><Borrelia burgdorferi sensu stricto><Borreliella burgdorferi><COVID-19 virus><COVID19 virus><Carditis><Clinic><Clinical><Clinical Data><Clinical Research><Clinical Study><CoV-2><CoV2><Data><Development><Encephalomyelitis><Engineering><Epitopes><Formulation><Funding><Goals><H Pertussis><H. Pertussis><Haemophilus pertussis><Health><Human><Hydrophobicity><Immune response><Immunological response><In Vitro><Infection><Infection prevention><Ixodida><Laboratories><Life><Lipoproteins><Lyme Borreliosis><Lyme Disease><Lyme Disease Spirochete><Lyme Disease Vaccines><Mammalia><Mammals><Measurement><Mediating><Membrane Protein Gene><Membrane Proteins><Membrane-Associated Proteins><Meningitis><Messenger RNA><Methodology><Mice><Mice Mammals><Mission><Modern Man><Murine><Mus><Muscle discomfort><Muscle pain><Muscle pain/fibrositis><Muscle sorenesss><Myalgia><Myalgic><Myeloencephalitis><Myodynia><Myoneuralgia><Myosalgia><NIH><National Institutes of Health><Organism><Parents><Peptide Vaccines><Peptides><Pertussis Vaccine><Phase><Prevent infection><Protein Region><Public Health><RNA vaccine><RNA-based vaccine><Recombinant Proteins><Recombinants><Research><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV2><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Secure><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Surface><Surface Proteins><Technology><Tick-Borne Diseases><Ticks><Time><Translations><United States><United States National Institutes of Health><Vaccination><Vaccine Antigen><Vaccine Production><Vaccines><Veterinarians><Work><Wuhan coronavirus><antigen challenge><arthritic><bacteria infection><bacterial disease><base><borrelial><cell mediated immune response><coronavirus disease 2019 virus><coronavirus disease-19 virus><cost><design><designing><develop a vaccine><develop vaccines><development of a vaccine><developmental><efficacy analysis><efficacy assessment><efficacy evaluation><efficacy examination><efficacy testing><enzootic><evaluate efficacy><examine efficacy><experiment><experimental research><experimental study><extracellular><global gene expression><global transcription profile><hCoV19><head-to-head analysis><head-to-head comparison><host response><immune system response><immunogen><immunogenicity><immunoresponse><in vivo><interest><lipid based nanoparticle><lipid nanoparticle><living system><lyme spirochete><lyme vaccine><mRNA><mRNA vaccine><mRNA-based vaccine><mouse model><murine model><nCoV2><new vaccines><next generation vaccines><novel><novel vaccines><parent project><pathogen><pre-clinical><preclinical><produce vaccines><recombinant peptide><response><stem><success><tick-borne illness><tickborne disease><tickborne illness><transcriptome><vaccination study><vaccination trial><vaccine development><vaccine formulation><vaccine platform><vaccine study><vaccine trial><vaccinology>